Retatrutide Dosing Schedule: The Week-by-Week Guide

The thing that stops most people is not the shot. It is the dose. How much do you start at? How fast do you go up? When do you stop? On the gray market you answer those alone, with calculators that disagree and a forum that mocks you for asking. This page lays out the plan Pep'd's prescribing clinicians follow, in plain numbers, and shows you why the math is their job, not yours.

One thing said plainly. Retatrutide is investigational and not FDA approved for any use. There is no FDA-approved dose. Because it was never approved, the FDA's position is that there is no legal basis under federal law to compound retatrutide, and it is not on the 503A bulk drug substances list, so we do not present compounded retatrutide as clearly legal or FDA-sanctioned. The dose plan below is provider-directed, not a label you follow on your own. A licensed provider sets your dose, raises it, and adjusts it for you.

What is the retatrutide dosing schedule?

The retatrutide dosing schedule is the plan for raising your weekly dose over time, paced by your provider. With Get Pep'd, you start at 2 mg a week and step up by 1 to 2 mg at a time, toward a target around 8 mg, only when your provider decides you are ready. The increase is not automatic every seven days. Women typically stay at 6 mg, men at 8 mg. A provider sets each step, so you are not guessing.

The plan is simple. Start at 2 mg a week, then step up by 1 to 2 mg at a time, at a pace your provider sets, toward about 8 mg. Women typically stay at 6 mg a week, men typically at 8 mg. The hold rule: if side effects show up, stay at your current dose until they pass, then raise it again. This is the Get Pep'd protocol, directed by the My Orbit Health prescribing clinicians. Steps are not fixed weeks. Your provider sets the pace and your maintenance dose.

This is the protocol the prescribing clinicians at My Orbit Health follow, the medical group behind Pep'd's care. It is built on one simple idea. You climb to the dose that works, one small step at a time, and you only step up when your body is ready. That is the whole plan in a sentence.

There is a reason it is built this way. Raising the dose slowly gives your body time to adjust, and it keeps side effects smaller. In the Phase 2 trial, the gut side effects clustered while the dose was climbing, and they tracked with the dose (Jastreboff et al., NEJM 2023).1 A slower climb is how a provider keeps you comfortable while the dose goes up.

What is the starting dose of retatrutide?

You start at 2 mg a week. That is the first step in Pep'd's protocol. You stay there long enough to see how your body takes it, then your provider raises the dose. Starting low and going slow is the safest way to begin a drug this strong.

People online argue about whether to start at 0.5 mg, 1 mg, or 2 mg, and they trade guesses because no one is in charge. One person wrote, "should I start at 1mg or 2mg, is 2mg too much to start." With a provider, that debate is over. They pick your starting dose and tell you when to move up. You do not have to settle it on a forum at midnight.

The community rule is "start low, go slow," and "never skip an escalation step." That is exactly what this protocol does. A small start, a slow climb, and a hold whenever your body asks for one.

How fast do you raise the retatrutide dose?

You step the dose up by 1 to 2 mg at a time, toward about 8 mg, at a pace your provider sets. The step is not automatic every seven days. The phase 2 trial reached its higher doses through gradual escalation, and side effects clustered during that climb (Jastreboff et al., NEJM 2023),1 so a faster ramp is not better. If you feel good, your provider moves you up. If side effects show up, you hold where you are until they pass, then take the next step when your provider says so.

Here is the hold rule, because it matters more than the climb. Side effects, mostly gut ones, show up while the dose is rising. When they do, you do not push through and you do not quit. You stay at your current dose until they settle, then take the next step. "Doubling up = doubling GI symptoms," as one user put it. The hold is how you avoid that.

Doing this alone, you guess at the pace and you pay for guessing wrong with nausea or worse. With a provider, the pace is a clinical call. Someone watches how you respond and adjusts the next step for you.

What is the maintenance dose, and should you push to 12 mg?

Most people stop climbing before the top. In Pep'd's protocol, women typically stay at 6 mg a week and men typically stay at 8 mg. That is your maintenance dose, the one you settle on once it controls your appetite. You do not have to reach the highest number to get the result.

This answers a fear people repeat: "Should I push to 12mg?" The honest answer is no, not just to chase a bigger number. The community phrase for it is "ride the lowest effective dose." If 6 or 8 mg keeps the food noise quiet and the weight moving, that is your dose. More drug means more side effects, not automatically more loss. Your provider helps you find the lowest dose that works and stay there.

One thing to reconcile, because our other pages cite the 12 mg trial numbers. The biggest trial weight-loss figures, up to 24.2% at 48 weeks and the 28.7% phase 3 topline, came from the 12 mg study dose, which is higher than the roughly 8 mg this provider-paced plan targets. The trial was finding the ceiling of what the molecule can do at the top dose. A real-world plan trades a little of that headline number for a gentler ramp and fewer side effects, which is the dose most people can actually stay on. Your provider sets where you land based on your response, not on the largest figure in a trial.

Ride the lowest dose that works. The goal is the result, not the biggest number on the vial.

How long will a 10 mg vial of retatrutide last?

It depends on your weekly dose, and the math is simple division. A 10 mg vial holds 10 mg of drug. Divide that by your weekly dose to get the number of weeks it covers. At 2 mg a week, a 10 mg vial lasts 5 weeks. At 3 mg a week, it lasts about 3.3 weeks. At 4 mg a week, it lasts 2.5 weeks. At 6 mg a week, about 1.7 weeks. At 8 mg a week, 1.25 weeks.

This is plain arithmetic, not a trial result. It tells you how far a vial stretches at a given dose. With prescribed care, you do not even run this math. Your provider sets the dose and the pharmacy fills and labels what you need, so you are not rationing a vial or stretching a dose to make supply last.

Why you are not doing the dose math yourself

The hardest part of doing this alone is not the schedule, it is turning the schedule into a shot, and with prescribed care a provider sets your dose and the pharmacy mixes and labels it, so the retatrutide overview walks through why that whole math problem disappears.

So when you read "start at 2 mg, raise by 1 to 2 mg, hold for side effects," read it as the plan your provider follows for you, not a recipe you have to get right alone.

How does this fit with the bigger retatrutide picture?

This dosing schedule is one piece of the retatrutide story. The drug works on three hormones at once, which is why people lost more weight in trials than on the drugs before it, and why the dose has to climb with care. The full picture lives on the retatrutide overview.

If you are switching from tirzepatide or semaglutide, your old dose does not carry over to retatrutide one-to-one. A provider sets your new starting dose and raises it on the same slow plan. Guessing the conversion is how people end up feeling nothing or, as one put it, "mega sick." See retatrutide vs tirzepatide, semaglutide, and Ozempic for how the drugs stack up before you switch.

Retatrutide is dosed once weekly, with a half-life that supports that schedule (Eli Lilly Medical).3 The same slow, provider-paced ramp applies whether you are starting fresh or coming off another drug.

This content is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA-approved for any use. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Trial figures cited here are average results from the named clinical trials, not a promise of individual results. A licensed provider determines whether any treatment is appropriate for you. Results vary.